Results From Tissue of Origin Test to be Presented at AACR-IASLC Conference
Results from a study involving Pathwork Diagnostics Inc’s Tissue of Origin Test will be presented at the AACR-IASLC Joint Conference.
Read MorePosted by Clinical Lab Products | Jan 10, 2012 | Cancer, Miscellaneous, Tissue Processing |
Results from a study involving Pathwork Diagnostics Inc’s Tissue of Origin Test will be presented at the AACR-IASLC Joint Conference.
Read MorePosted by Clinical Lab Products | Oct 11, 2011 | Molecular Diagnostics |
ARUP LaboratoriesBiohit IncBioneer IncMitsubishi Chemical Medience CorpSiemens Healthcare DiagnosticsHoefer IncAbbottArlington Scientific IncEraGen Biosciences
Read MorePosted by Clinical Lab Products | Sep 6, 2011 | Cancer, Miscellaneous |
Judy O’Rourke We wish we could be across the room, asking what you think about things. Plan B is the recent survey we conducted in partnership with the research department at Mizuho Securities USA, asking where you think personalized med
Read MorePosted by Clinical Lab Products | Sep 3, 2011 | Cancer, Clinical Chemistry, Clinical Chemistry Analyzers, Clinical Chemistry Test Kits, Miscellaneous |
Update on how some companies are embracing personalized medicine in oncology testing
Read MorePosted by Clinical Lab Products | Aug 29, 2011 | Cancer, Miscellaneous |
The new Abbott Vysis ALK Break Apart FISH Probe test is designed to identify ALK-positive NSCLC patients for Pfizer’s approved NSCLC therapy, XALKORI (crizotinib), an oral ALK inhibitor.
Read More